Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is fundamentally attractive because it combines a proven, revenue-generating RNAi franchise with a deep pipeline that can extend growth across rare disease, cardio-metabolic, and hematology markets, while partner-led assets like Leqvio and Qfitlia broaden its commercial reach without requiring full internal commercialization. Its TTR franchise remains a core strength, with management and analysts citing roughly 200,000 underdiagnosed U.S. ATTR-CM patients, more than 80% of whom remain untreated, and the data suggest category growth is being driven by expanding diagnosis and treatment rather than demand erosion, even as pricing normalizes. The outlook is further reinforced by a large-scale hypertension opportunity in ZENITH, where more than 200 million adults across the seven major markets have hypertension, roughly one-third are at high CV risk, and up to 80% remain uncontrolled despite multiple oral agents, alongside additional upside from bleeding-disorder programs in HHT and VWD that address major unmet needs and meaningful global patient populations.

Alnylam Pharmaceuticals is facing a fundamentally challenging risk-reward setup because much of its valuation depends on a broad pipeline with uneven probabilities of success, while key programs such as zilebesiran still lack the human REVERSIR data and clear answers on the potassium-screening requirement that would support durable adoption. Although the company has meaningful commercial assets and a strong cardiology buy-and-bill footprint—helped by LEQVIO’s 55% U.S. growth in the last quarter and roughly 90% of ATTR-CM patients treated close to home—the business still carries material execution, reimbursement, and profitability risk, especially given the U.S. Attorney’s Office subpoena tied to government price reporting and distributor fee/discount arrangements. Even with a modeled total firm value of $63 billion, the reliance on high-confidence assumptions for AMVUTTRA, nucresiran, and QFITLIA, alongside only 50% success assigned to zilebesiran and 15% to ALN-HSD, highlights a portfolio that remains vulnerable to clinical setbacks, competitor pressure, and dilution or margin compression if commercialization does not scale as expected.